WO1993023164A1 - Separation method - Google Patents
Separation method Download PDFInfo
- Publication number
- WO1993023164A1 WO1993023164A1 PCT/DK1993/000159 DK9300159W WO9323164A1 WO 1993023164 A1 WO1993023164 A1 WO 1993023164A1 DK 9300159 W DK9300159 W DK 9300159W WO 9323164 A1 WO9323164 A1 WO 9323164A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- catalyst
- acid
- reaction mixture
- solid
- reaction
- Prior art date
Links
- 238000000926 separation method Methods 0.000 title description 23
- 238000000034 method Methods 0.000 claims abstract description 92
- 239000011541 reaction mixture Substances 0.000 claims abstract description 75
- 238000006243 chemical reaction Methods 0.000 claims abstract description 47
- 239000007787 solid Substances 0.000 claims abstract description 32
- 239000011949 solid catalyst Substances 0.000 claims abstract description 20
- 239000003054 catalyst Substances 0.000 claims description 85
- 239000002245 particle Substances 0.000 claims description 54
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 51
- 230000010933 acylation Effects 0.000 claims description 36
- 238000005917 acylation reaction Methods 0.000 claims description 36
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 239000000047 product Substances 0.000 claims description 32
- 239000007858 starting material Substances 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229960000723 ampicillin Drugs 0.000 claims description 12
- 239000012265 solid product Substances 0.000 claims description 12
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 claims description 11
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 claims description 11
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- LJCWONGJFPCTTL-SSDOTTSWSA-N D-4-hydroxyphenylglycine Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC=C(O)C=C1 LJCWONGJFPCTTL-SSDOTTSWSA-N 0.000 claims description 7
- 108090001109 Thermolysin Proteins 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 108700023418 Amidases Proteins 0.000 claims description 5
- 102000005922 amidase Human genes 0.000 claims description 5
- GCOOGCQWQFRJEK-UHFFFAOYSA-N 2-thiophen-3-ylpropanedioic acid Chemical compound OC(=O)C(C(O)=O)C=1C=CSC=1 GCOOGCQWQFRJEK-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 claims description 4
- 239000011343 solid material Substances 0.000 claims description 4
- SMJRBWINMFUUDS-UHFFFAOYSA-N 2-thienylacetic acid Chemical compound OC(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 230000003134 recirculating effect Effects 0.000 claims description 3
- DPUJHFCZDZYLRW-HWZXHQHMSA-N (6r)-7-amino-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(OC)=C(C(O)=O)N2C(=O)C(N)[C@@H]12 DPUJHFCZDZYLRW-HWZXHQHMSA-N 0.000 claims description 2
- OQSAFIZCBAZPMY-AWFVSMACSA-N (6r,7r)-7-azaniumyl-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S1CC(Cl)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@H]21 OQSAFIZCBAZPMY-AWFVSMACSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 2
- 108090000371 Esterases Proteins 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004494 ethyl ester group Chemical group 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- VSDUZFOSJDMAFZ-UHFFFAOYSA-N methyl 2-amino-3-phenylpropanoate Chemical compound COC(=O)C(N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- -1 isopropyl ester Chemical class 0.000 claims 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 230000003115 biocidal effect Effects 0.000 description 18
- 239000013078 crystal Substances 0.000 description 18
- 239000012295 chemical reaction liquid Substances 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000002002 slurry Substances 0.000 description 11
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 108010073038 Penicillin Amidase Proteins 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 7
- 229960003022 amoxicillin Drugs 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 229940106164 cephalexin Drugs 0.000 description 6
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- NVIAYEIXYQCDAN-CLZZGJSISA-N 7beta-aminodeacetoxycephalosporanic acid Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](N)[C@@H]12 NVIAYEIXYQCDAN-CLZZGJSISA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000002132 β-lactam antibiotic Substances 0.000 description 5
- 229940124586 β-lactam antibiotics Drugs 0.000 description 5
- YSCNREZXFSZAQO-ROUUACIJSA-N (3s)-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxo-3-(phenylmethoxycarbonylamino)butanoic acid Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](CC(O)=O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 YSCNREZXFSZAQO-ROUUACIJSA-N 0.000 description 4
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BHFLUDRTVIDDOR-MRVPVSSYSA-N methyl (2r)-2-amino-2-phenylacetate Chemical compound COC(=O)[C@H](N)C1=CC=CC=C1 BHFLUDRTVIDDOR-MRVPVSSYSA-N 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000286904 Leptothecata Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- SWVMLNPDTIFDDY-FVGYRXGTSA-N methyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-FVGYRXGTSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WQFROZWIRZWMFE-SSDOTTSWSA-N (2r)-2-amino-2-(4-hydroxyphenyl)acetamide Chemical compound NC(=O)[C@H](N)C1=CC=C(O)C=C1 WQFROZWIRZWMFE-SSDOTTSWSA-N 0.000 description 2
- XYXYXSKSTZAEJW-VIFPVBQESA-N (2s)-2-(phenylmethoxycarbonylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 XYXYXSKSTZAEJW-VIFPVBQESA-N 0.000 description 2
- 241000589212 Acetobacter pasteurianus Species 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000589634 Xanthomonas Species 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229950011260 betanaphthol Drugs 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 210000001822 immobilized cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- KIYRSYYOVDHSPG-SSDOTTSWSA-N (2r)-2-amino-2-phenylacetamide Chemical compound NC(=O)[C@H](N)C1=CC=CC=C1 KIYRSYYOVDHSPG-SSDOTTSWSA-N 0.000 description 1
- MEAZEHJUPLREOQ-SSDOTTSWSA-N (2r)-2-amino-2-phenylacetyl chloride Chemical compound ClC(=O)[C@H](N)C1=CC=CC=C1 MEAZEHJUPLREOQ-SSDOTTSWSA-N 0.000 description 1
- SBUCDZYLTRYMFG-PBFPGSCMSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](N)C=3C=CC(O)=CC=3)[C@H]2SC1 SBUCDZYLTRYMFG-PBFPGSCMSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- UUPZTFTUZUQRQT-UHFFFAOYSA-N 2-thiophen-2-ylacetamide Chemical compound NC(=O)CC1=CC=CS1 UUPZTFTUZUQRQT-UHFFFAOYSA-N 0.000 description 1
- 150000005394 2-thiopheneacetic acids Chemical class 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000726092 Aphanocladium Species 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000588773 Kluyvera cryocrescens Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000586779 Protaminobacter Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940047526 cephalexin monohydrate Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CVWJDUUVFSVART-SECBINFHSA-N ethyl (2r)-2-amino-2-(4-hydroxyphenyl)acetate Chemical compound CCOC(=O)[C@H](N)C1=CC=C(O)C=C1 CVWJDUUVFSVART-SECBINFHSA-N 0.000 description 1
- VWKGPFHYXWGWEI-SECBINFHSA-N ethyl (2r)-2-amino-2-phenylacetate Chemical compound CCOC(=O)[C@H](N)C1=CC=CC=C1 VWKGPFHYXWGWEI-SECBINFHSA-N 0.000 description 1
- QSUANHXENVRFDN-UHFFFAOYSA-N ethyl 2-thiophen-2-ylacetate Chemical compound CCOC(=O)CC1=CC=CS1 QSUANHXENVRFDN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000003622 immobilized catalyst Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- SZBDOFWNZVHVGR-MRVPVSSYSA-N methyl (2r)-2-amino-2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)[C@H](N)C1=CC=C(O)C=C1 SZBDOFWNZVHVGR-MRVPVSSYSA-N 0.000 description 1
- VSDUZFOSJDMAFZ-SECBINFHSA-N methyl (2r)-2-amino-3-phenylpropanoate Chemical compound COC(=O)[C@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-SECBINFHSA-N 0.000 description 1
- KNKIXYMOHMYZJR-UHFFFAOYSA-N methyl 2-thiophen-2-ylacetate Chemical compound COC(=O)CC1=CC=CS1 KNKIXYMOHMYZJR-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001749 primary amide group Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QMARIUUSBJNLKK-SNVBAGLBSA-N propan-2-yl (2R)-2-amino-2-(4-hydroxyphenyl)acetate Chemical compound C(C)(C)OC([C@H](N)C1=CC=C(C=C1)O)=O QMARIUUSBJNLKK-SNVBAGLBSA-N 0.000 description 1
- ZKEXQEOLDNOTPG-SNVBAGLBSA-N propan-2-yl (2r)-2-amino-2-phenylacetate Chemical compound CC(C)OC(=O)[C@H](N)C1=CC=CC=C1 ZKEXQEOLDNOTPG-SNVBAGLBSA-N 0.000 description 1
- DODXDRHBJVNPAE-SNVBAGLBSA-N propyl (2R)-2-amino-2-(4-hydroxyphenyl)acetate Chemical compound C(CC)OC([C@H](N)C1=CC=C(C=C1)O)=O DODXDRHBJVNPAE-SNVBAGLBSA-N 0.000 description 1
- OTVFBDVSAVOXGJ-SNVBAGLBSA-N propyl (2r)-2-amino-2-phenylacetate Chemical compound CCCOC(=O)[C@H](N)C1=CC=CC=C1 OTVFBDVSAVOXGJ-SNVBAGLBSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 150000003511 tertiary amides Chemical class 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J38/00—Regeneration or reactivation of catalysts, in general
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/009—Preparation by separation, e.g. by filtration, decantation, screening
Definitions
- the present invention relates to a method of separating a particulate solid catalyst from a chemical reac- tion mixture which further comprises at least one other solid component, either during the reaction or after the reaction.
- Separation of a precipitate from a liquid is a well known process which can be carried out by decantation, filtration or centrifugation.
- a reaction mixture contains two or more different solid components
- solid components can be separated from each other by mechanical processes like floatation.
- Other methods are physicochemical methods like extraction or partition, which utilize a difference in solubility of the components e.g. in water, in aqueous acid, in aqueous base or in organic solvents.
- a pre ⁇ requisite of the applicability of these methods is that con ⁇ ditions can be found under which the components to be separ ⁇ ated are stable.
- the price of the catalyst is often a very important parameter in the overall economy of the process. Therefore, it is an advantage of major importance if the catalyst can be reused without significant loss of catalytic activity.
- the catalyst is present in a reaction mixture together with another solid component which is either formed during the reaction, such as a by-product or the desired product, or present during the whole process, e.g. a solid starting material added in excess, the isolation and reuse of the catalyst is hampered.
- the catalyst can sometimes be iso ⁇ lated by extracting the other soli (s) with organic solvents and/or with acids or bases which will dissolve the soli (s) except for the catalyst.
- activity of catalysts including enzymes, is very sensitive to the presence of so- called catalyst poisons.
- Catalyst poisons exert their activi ⁇ ty e.g. by binding very strongly to the catalyst or by de- composing it.
- strong acids and bases often have an adverse effect on the activity of catalysts and particularly enzymes generally suffer irreversible damage on exposure to high concentrations of acids or bases.
- This imposes certain limitations on the use of acids and bases in the work up of reaction mixtures from enzymatic reactions when the enzyme is to be recycled without significant loss of activity.
- Other limitations on the work up conditions may of course be im ⁇ posed by the nature of the desired product which may itself be a labile compound.
- the prior art does not indicate a satisfactory solution to the separation problems outlined above.
- the catalyst can, according to the present invention, be separated almost quantitatively by sieving or filtering the reaction -mixture after the reaction is considered to be finished or, optionally, in a continuous way.
- catalyst particles of a well defined particle size range are used and the other solid componen (s) of the reaction mixture has (have) a particle size smaller than the lower limit of the apparent particle size range of the catalyst.
- the separation of the catalyst is then carried out by letting the slurry which con ⁇ stitutes the reaction mixture pass through a sieve or a filter which will retain the catalyst particles and let the remainder of the mixture pass through. This can be done either in a batchwise or in a continuous way.
- the separation of the solid components may be facilitated if the filter plate or sieve is vibrated during the separation or if the slurry on the filter plate is stirred. After the catalyst has been separated the remainder of the reaction mixture can be filtered on a filter which will retain the remaining solid component(s) .
- the relative amounts of the desired product found in the filter cake and in the filtrate depends on the solubility of the desired product in the reaction medium.
- the filtrate and the filter cake can be worked up separately, some components optionally being recirculated in the process together with the catalyst.
- the present inven ⁇ tion relates to a method of separating a particulate solid catalyst from a reaction mixture which further comprises at least one other particulate solid component and a liquid by giving one of the particulate solid components an apparent particle size which is outside the apparent particle size range of the other solid component(s) whereupon the reaction mixture is filtered or centrifuged using equipment which will retain the component(s) having the larger particles and let the remainder of the mixture pass through.
- the solid componen (s) to be separated from the catalyst has (have) an apparent particle size smaller than the lower limit of the apparent particle size range of the catalyst.
- the ratio between the apparent diameter of the larger particles and the apparent diameter of the smaller particles to be separated is at least 2.
- the apparent particle diameter of the catalyst is in the range of from 25 to 10,000 ⁇ m, preferably from 50 to 750 ⁇ m, more preferred from 50 to 300 ⁇ m.
- the solid catalyst is an immobilized enzyme. In a further preferred embodiment of the inven ⁇ tion the solid catalyst is an immobilized protease.
- the solid catalyst is an immobilized metalloprotease.
- the solid catalyst is an immobilized serine protease.
- the solid catalyst is immobilized thermolysin.
- the solid catalyst is an immobilized amidase. In a further preferred embodiment of the inven ⁇ tion the solid catalyst is an immobilized esterase. In a further preferred embodiment of the inven ⁇ tion the solid catalyst is an immobilized acylase.
- the solid catalyst is an immobilized enzyme which is able to deacylate the 6-amino group of penicillin G.
- the solid catalyst is an immobilized enzyme which is able to deacylate the 6-amino group of ampicillin.
- the immobilized enzyme is a penicillin G acylase.
- the immobilized enzyme is an ampicillin hydrolase.
- the solid catalyst is an immobilized whole cell prepara- tion.
- the solid catalyst is an immobilized cell homogenate preparation.
- a solid product produced in a process in which the starting material(s) is (are) fully dissolved in the reaction mixture is separated continuously from the catalyst during the reaction by leading the filtrate from the filter which retains the catalyst only to a filter which retains the solid product synthesized and recirculating the filtrate from this filter to the catalyst.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of a ⁇ -lactam antibiotic nucleus with the acid corresponding to the side chain or a derivative of this acid from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 6-amino group in 6-amino- penicillanic acid from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 7-amino- cephalosporanic acid from the remainder of the reaction mix ⁇ ture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 7-amino-7- methoxycephalosporanic acid from the remainder of the reac ⁇ tion mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 7-amino-3- methoxy-3-cephem-4-carboxylic acid from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 7-amino- desacetoxycephalosporanic acid from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 3-chloro-7— amino-3-cephem-4-carboxylic acid from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 7-amino-3-
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of the 7-amino group in 7-amino-3-
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with D-phenylglycine as the acylating agent from the re- mainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with a derivative of D-phenylglycine as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a ⁇ -lactam antibiotic nucleus with D-phenylglycine amide as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a ⁇ -lactam antibiotic nucleus with D-phenylglycine methyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with D-phenylglycine ethyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a ⁇ -lactam antibiotic nucleus with D-phenylglycine propyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /?-lactam antibiotic nucleus with D-phenylglycine isopropyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a 3-lactam antibiotic nucleus with D-4-hydroxyphenylglycine as the acylating agent from the remainder of the reaction mixture. In a further preferred embodiment, the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with a derivative of D-4-hydroxyphenylglycine as the acylat- ing agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with D-4-hydroxyphenylglycine amide as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with D-4-hydroxyphenylglycine methyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with D-4-hydroxyphenylglycine ethyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a ⁇ -lactam antibiotic nucleus with D-4-hydroxyphenylglycine propyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with D-4-hydroxyphenylglycine isopropyl ester as the acylat- ing agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a 0-lactam antibiotic nucleus with 2-thiopheneacetic acid as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a 3-lactam antibiotic nucleus with a derivative of 2-thiopheneacetic acid as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a 0-lactam antibiotic nucleus with 2-thiopheneacetic acid amide as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a 3-lactam antibiotic nucleus with 2-thiopheneacetic acid methyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with 2-thiopheneacetic acid ethyl ester as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with 3-thiophenemalonic acid as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the acylation of a /3-lactam antibiotic nucleus with a derivative of 3-thiophenemalonic acid as the acylating agent from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of L-phenylalanine methyl ester with a L-aspartic acid derivative in which the amino group is pro ⁇ tected from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing acylation of D,L-phenylalanine methyl ester with a L-aspartic acid derivative in which the amino group is protected from the remainder of the reaction mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the hydrolysis of an amide or an ester of an amino carboxylic acid to provide the corresponding free acid or a salt thereof from the remainder of the reaction mixture when the hydrolysis is conducted at such conditions that the product formed or a part thereof precipitates from the reac ⁇ tion mixture.
- the invention relates to a method of separating an immobilized enzyme used for catalyzing the conversion of fumaric acid or a salt thereof to malic acid or a salt thereof from the solid product obtained when the reaction is conducted at such con- ditions that the product formed or a part thereof precipi ⁇ tates from the reaction mixture.
- the separation method according to the present invention is particularly useful when a heterogeneous cata- lyst, e.g. a solid, particulate, immobilized enzyme, is to be separated from a reaction mixture which further contains at least one other particulate, solid component.
- This other par ⁇ ticulate, solid component can either be a product synthesized under the influence of the catalyst or it can be unreacted starting material e.g. a starting material added in excess.
- the word product when not further specified can mean either the desired product or a by-product resulting from a reaction.
- the catalyst When the catalyst is the only solid component present in the reaction mixture at the beginning of the reac ⁇ tion and the product is sparingly soluble in the liquid ⁇ art of the reaction mixture the catalyst can be separated from the reaction mixture by giving the solid product particles an apparent particle size which is outside the apparent particle size range of the solid catalyst particles whereupon the re ⁇ action mixture is filtered or centrifuged using a filter or a centrifuge which will retain the component having the larger particles and let the remainder of the reaction mixture pass through.
- the liquid part of the reaction mixture is designated "the reaction liquid” or just "the liquid”.
- the reaction liquid thus comprises the solvent (or solvent mixture) in which the reaction is conducted and the dissolved part of starting materials and products be they solids or liquids.
- the separation of the catalyst from the remainder of the re ⁇ action mixture can be performed in a continuous way by leading the filtrate from the filter which retains the cata ⁇ lyst only to a filter which retains the solid product syn ⁇ thesized and recirculating the filtrate from this filter to the catalyst. In this way the equilibrium of the reaction is influenced towards a higher yield.
- One or more starting materials may be sparingly soluble in the solvent in which the reaction is performed. In this case the starting material(s) may be present in solid form in the reaction mixture and the reaction liquid will then be saturated with respect to the pertinent component(s) .
- the problem to be solved by the present invention during the working up is to separate the catalyst from the reaction liquid containing solid, unreacted starting material. If the product is also sparingly soluble in the reaction liquid the product and the unreacted starting material will have to be separated from each other after the catalyst has been separated from the remainder of the reac ⁇ tion mixture.
- the true dimension of particles like crystals can be determined e.g. by using a microscope equipped with a suitable scale. Particles come in many different shapes. Thus crystals can e.g. be needle-like, plate-like or cubic.
- the important feature in the present context is not the true dimension of the particles but rather the apparent dimension e.g. stated as the apparent diameter.
- the designation "apparent dimension” or "apparent dia- meter” is used to reflect how a particle behaves on a sieve or a filter.
- the apparent diameter of a particle cor ⁇ responds to the diameter of a hole or a pore which in prac ⁇ tical use will just allow the particle to pass through it.
- the particle size of the catalyst is reduced as much as the separation procedure allows. This helps to ensure a high activity of the catalyst and helps to eliminate diffusion problems.
- the solid catalyst to be used according to the present method may exist in the form of a particulate immobi ⁇ lized enzyme preparation and may have a density higher or lower than that of the reaction liquid. In this preparation, the enzyme may be adsorbed, absorbed, covalently bound, entrapped or bound by ionic forces.
- Methods for immobilizing enzymes are known in the art. The known art also provides methods for preparing particles for carrying immobilized catalysts e.g. enzymes and for isolating various fractions of particulate solids according to their particle size distribu ⁇ tion.
- the specific catalyst to be used in each case depends on the process to be conducted. The process of this invention is generally carried out in water. Optionally, organic solvents can be added.
- Organic solvents are preferably selected among water- miscible solvents such as methanol, ethanol, 1-propanol, 2- propanol, 1-butanol, 1,4-butanediol, acetone, acetonitrile, N,N-dimethylformamide and dimethylsulfoxide.
- water- miscible solvents such as methanol, ethanol, 1-propanol, 2- propanol, 1-butanol, 1,4-butanediol, acetone, acetonitrile, N,N-dimethylformamide and dimethylsulfoxide.
- the temperature is one of the parameters which influences the size of the particles when a solid product is formed. This can be because the growth rate of the crystals depends on the temperature or in some cases because different crystal modifications occur at different temperatures.
- the freezing point of the reaction liquid forms the absolute lower temperature limit for carrying out the method of the present invention. If the catalyst used is an immobilized enzyme the absolute upper temperature limit for carrying out the method will usually depend on the enzyme.
- Examples of specific areas within which the present invention leads to essential improvements are: 1) Preparation of semisynthetic penicillins and cephalosporins, 2) Hydrolysis of amides and esters and 3) Synthesis of pep ⁇ tides.
- Examples of /3-lactam antibiotics penicillins and cephalosporins which can be prepared with advantage using the method of the present invention are ampicillin, amoxi- cillin, ticarcillin, cefaclor, cefatrizine, cefaparol, cephalexin, cefadroxil, cephaloglycin and cephalothin.
- semisynthetic /3-lactams are prepared in industry by chemical methods.
- Penicillins for example, are prepared by reacting 6-APA, usually having its carboxyl group protected, with an activated side chain derivative, followed by removal of the protecting groups by hydrolysis.
- ampicillin can be prepared by reacting 6-APA, having a suit ⁇ ably protected carboxylic acid group, with D-phenylglycyl chloride, followed by hydrolytic removal of the group which protects the carboxylic acid group.
- These reactions typically involve costly steps such as the use of temperatures below 0°C (in certain cases even below -25°C) , silylation reagents and organic solvents like methylene chloride, which must be handled with care since they are injurious to health and harmful to the environment.
- Enzymatic production of semisyntetic /3-lactam antibiotics by acylation of a / 3-lactam nucleus with a deriva ⁇ tive (such as a lower alkyl ester) of D-phenylglycine or D-4- hydroxyphenylglycine is known e.g. from DE patent application No. 2,163,792, AT patent No. 243,986, NL patent application No. 70-09138, DE patent application No. 2,621,618 and EP patent application publication No. 339,751.
- Processes de ⁇ scribed in the prior art have typically been conducted at concentrations below 300 mM of the D-phenylglycine derivative and below 25 mM of the /3-lactam nucleus. This rather low concentration of the starting materials is a potential drawback of these known methods for enzymatic production of semisynthetic /3-lactam antibiotics
- the yields re ⁇ ported are low, typically less than 85%, and a process for recycling the unreacted / 3-lactam nucleus is ret..red, which leads to more and costly unit operations.
- the need then arises to separate the catalyst from the reaction mixture containing solid products and/or unreacted starting materials, before the remainder of the reaction mixture is further worked up as the working up may involve conditions harmful to the enzyme activity, for example, dissolution of products and unreacted starting materials at a low pH value (e.g. at a pH value of 50.5 - 2.0) .
- the acylating agent used for introducing the sidechain in a /3-lactam antibiotic nucleus i.e. for introduc ⁇ ing the acyl group in the 6-amino group of the penicillins or in the 7-amino group of the cephalosporins can be the corre-
- the methyl ester, the ethyl ester, and the amide are preferred.
- the derivative may be used in the free form or in the form of a salt, for
- the enzyme to be used may be any enzyme catalyz ⁇ ing the reaction in question. Such enzymes are usually termed penicillin amidases, penicillin acylases, or ampicillin hydrolases. A number of microbial enzymes known to have this
- 20 activity are derived from, for example, Acetobacter. Xantho- monas, Mvcoplana. Protaminobacter, Aero onas DE patent appli ⁇ cation No. 2,163,792) Pseudo onas (AT patent No. 243,986), Flavobacterium (NL patent application No. 70-09138) , Aphano- cladium, Cephalosporium (DE patent application No.
- Acetobacter pasteurianus DE patent application No. 2,163,792 A
- Acetobacter turbidans Takahashi et al. , Biochem.J. 137 (1974), 497 - 503
- Pseudomonas melanogenum Kim & Byun, Biochim.Biophys. Acta, 1040 (1990) , 12 - 18)
- Xanthomonas citrii EP patent application publication No.
- the catalyst can be reused, optionally after having gone through a washing procedure. Products and optio ⁇ nal unreacted starting material can be separated and worked up separately or recycled respectively.
- ZAPM N-benzyloxycarbonyl-L-aspartyl-L-phenylalanine methyl ester
- one of the critical steps involves an enzyme cata ⁇ lyzed coupling of an aspartic acid derivative and phenyl- alanine methyl ester hydrochloride (for example coupling N- benzyloxycarbonyl-L-aspartic acid and L-phenylalanine methyl ester hydrochloride to form ZAPM.
- the ZAPM forms a very sparingly soluble addition compound with L-phenylalanine methyl ester (or D-phenylalanine methyl ester, if present) and therefore precipitates during the synthesis.
- the equili ⁇ brium of the reaction is hereby shifted towards condensation.
- a semi-purified, soluble enzyme preparation e.g. thermolysin
- the reaction product is dissolved and the enzyme is precipitated by addition of an organic solvent (for example acetone) and removed, for example, by filtration.
- an organic solvent for example acetone
- Immobilized penicillin G acylase from E. coli 250 g, Eupergit ® -PcA, obtained from Rohm Pharma
- E. coli 250 g, Eupergit ® -PcA, obtained from Rohm Pharma
- the material retained on the 180 ⁇ m screen was used as the enzyme catalyst in the examples 2-5 given below.
- the activity of the catalyst was 115 penicil ⁇ lin G acylase Units (U) per g of moist catalyst.
- D-phenylglycine methyl ester in the following designated D-PGM
- 6-aminopenicillanic acid in the fol ⁇ lowing designated 6-APA
- the temperature of the suspension was brought to 35 °C and 10.0 g of moist immobilized enzyme (according to Example 1) was added, the total volume being 100 ml.
- the reaction was allowed to proceed with efficient stirring at 35 °C, the pH value being kept at 6.0 by titration with 2 M H 2 S0 4 .
- D-phenylglycine in the following designated D-PG
- D-PG D-phenylglycine
- the ampicillin concentration reached a maximum of 77 mM, corre ⁇ sponding to 85% conversion of the 6-APA.
- the contents of the reaction vessel were transferred to a filter unit having a 100 ⁇ m pore size screen as the bottom and a rotating propeller placed immediately above the screen.
- the immobilized enzyme was retained by the screen while the remaining part of the slurry passed through.
- the precipitate in this filtrate consisted of D-phenylglycine crystals con ⁇ taining some ampicillin and the liquid contained i.a. dis- solved product and unreacted starting materials.
- the ampicil ⁇ lin crystals formed had a particle size of less than 50 ⁇ m.
- the filtrate i.e. the slurry comprising the crystals and the reaction liquid
- the clear centrifugate was used to wash off crystals remaining on the catalyst.
- the catalyst was kept in suspension at all times during the separation. When no crystals could be seen in the catalyst fraction the tank was drained completely, leaving only the catalyst on the screen.
- Eluent A 25 mM phosphate buffer, pH value 6.5.
- Eluent B acetonitrile.
- D-phenylglycine methyl ester, HCl-salt, (1.6526 g) and 7-aminodesacetoxycephalosporanic acid (7-ADCA) (0.4278 g) were dissolved in 50 mM phosphate buffer (pH value: 6.5) and thermostated to 35°C.
- Enzyme catalyst according to Example 1 (2 g) was added and the volume of the reaction mix ⁇ ture was adjusted to 20 ml with buffer. The reaction was allowed to proceed under efficient mixing, keeping the pH value and temperature constant.
- cephalexin was isolated and purified by known methods. More than 99% of the catalytic activity was retained in the catalyst after the separation step and the catalyst was thus suitable for reuse. A rinsing step may be introduced before the catalyst is reused.
- the concentration of amoxicillin reached a maximum corresponding to 85% conversion and the reaction mixture contained, i.a. , crystals of amoxicillin, D- 4-hydroxyphenylglycine (in the following designated HPG) and unreacted HPGA.
- HPG D- 4-hydroxyphenylglycine
- the recirculation of the filtrate to the reaction vessel was stopped and instead the filtrate was led to a centrifuge. As described in the previous two examples the clear supernatant was used for washing off the last crystals from the catalyst.
- amoxicil- lin was further purified by methods known in the art.
- the catalyst used was suitable for reuse since more than 99% of its catalytic activity was retained.
- the fil ⁇ trate from this separation comprised the precipitated HPG and the supernatant which contained, i.a. , salts and dissolved HPG. In total 96% of the HPG formed was found in the fil ⁇ trate.
- the HPG was further purified by known methods.
- the catalyst in the reaction vessel was washed with 50 mM phosphate buffer (pH value: 6.0) and was reused without a significant loss of catalytic activity (less than 1% of the total activity was lost during the synthesis and subsequent separation) .
- thermolysin catalyst Preparation of a thermolysin catalyst.
- Thermolysin (8 g, Sigma P-1512) was dissolved in 25 mM of phosphate buffer (pH value: 7) to approximately 50 mg protein per ml and approximately 3750 U (vide infra) per ml.
- Cells from an E. coli fermentation e.g. A. Gebauer et al. - Bioprocess Engineering 2. (1987) 55-58
- the thermo ⁇ lysin was added to the cells which were immobilized as described in W ⁇ mpelmann, M. et al. US patent No. 4,892,825 (to Novo Industri A/S) .
- the material carrying the immobilized cells was extruded and dried to approximately 10% water con ⁇ tent. The resulting particles were milled and the milled material was sieved. The 75 - 150 ⁇ m particle size fraction was used as catalyst in the synthesis of N-benzyloxycarbonyl- L-aspartyl-L-phenylalanine methyl ester. The activity of the catalyst was approximately 3000 U per g. The activity was measured by the casein digestion method (1 unit (U) will hydrolyze casein to produce color equivalent to 1.0 ⁇ ole of tyrosine per minute at a pH value of 7.5 at 35°C (color by Folin-Ciocalteu reagent) ) .
- N-benzyloxycarbonyl-L-aspartic acid (0.1 mole) and L-phenylalanine methyl ester hydrochloride (0.25 mole) was dissolved in water and adjusted to a pH value of 6.5 and a final volume of 350 ml.
- the solution was thermostated at 40°C and catalyst prepared as described above (15 g) was added.
- the catalyst was swelled in water before use, whereby the particle size increased to approximately 150-400 ⁇ m.
- the reaction was allowed to proceed at 40"C keeping the pH value constant at 6.5 and maintaining an efficient low shear stirring.
- the condesation product, N-benzyloxycarbonyl-L- aspartyl-L-phenylalanine methyl ester forms an addi- tion compound with unreacted L-phenylalanine methyl ester which has a very poor solubility in water. Accordingly, the product precipitated almost quantitatively as this addition compound gradually as it was formed.
- the reaction mixture was cooled to approximately 5°C and trans- ferred to the separation unit described in Example 2.
- the catalyst was separated from the product and the reaction liquid as described in Example 2.
- the catalyst in the reac ⁇ tion vessel can be reused as more than 99% of the total cata ⁇ lytic activity was retained after the separation step.
- ZAPM can be further processed to aspartame by methods known per se (removal of the N-protection group of the aspartic moiety, crystallization etc.).
- E. coli having Penicillin G acylase activity was fermented according to Gebauer, A. et al. Bioprocess Engi ⁇ neering 2 (1987) 55-58. Immobilization was performed according to W ⁇ mpelmann, M. et al. US Patent No. 4,892,825 (to Novo Industri A/S) .
- the substance containing the immo ⁇ bilized enzyme was extruded and dried until the residual water content was approximately 10 % (w/w) .
- the dried mate ⁇ rial was milled and a fraction having a particle size distri ⁇ bution of 100-200 ⁇ m was obtained from the milled product by the use of appropriate sieves.
- the enzyme activity in this fraction was found to be approximately 200 Penicillin G acylase Units/g. After swelling in water, the particle size distribution was approximately 200-500 ⁇ m.
- the reaction mixture was poured on to a 100 ⁇ m pore screen, which retained the particles carrying the enzyme while the remaining part of the reaction mixture, still a slurry, passed through.
- the slurry passing the screen was filtered on a sintered glass filter which retained the solid material and some of the mother liquor was used to wash the solid material remaining on the 100 ⁇ m screen in order to free the enzyme particles from any adhering fine slurry containing the synthesized product. Also the washings were filtered through the sintered glass filter.
- the product collected on the glass filter was washed with butyl acetate (200 ml) and then suspended in a mixture of water (150 ml) and butyl acetate (150 ml) .
- the pH value of the water phase was adjusted to 1.5 by addition of 3 M sul ⁇ furic acid and stirring was continued for 10 minutes.
- the water phase was then separated from the butyl acetate phase and washed with further butyl acetate (2x20 ml) .
- the volume of the water phase was reduced to 75 ml by evaporation, 2- propanol (75 ml) was added and the pH value was adjusted to 4.7 by addition of 4 M ammonium hydroxide.
- the slurry ob ⁇ tained was cooled to 5 °C for 15 minutes, whereupon the solid material was collected on a sintered glass filter and washed with water/2-propanol (1:1, 25 ml).
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Catalysts (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1342-94A SK134294A3 (en) | 1992-05-14 | 1993-05-13 | Method of separation of particle solid catalyst |
EP93909823A EP0640014A1 (en) | 1992-05-14 | 1993-05-13 | Separation method |
JP5519788A JPH07507959A (en) | 1992-05-14 | 1993-05-13 | Separation method |
BR9306349A BR9306349A (en) | 1992-05-14 | 1993-05-13 | Process for separating a particulate solid catalyst from a reaction mixture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK64192A DK64192D0 (en) | 1992-05-14 | 1992-05-14 | SEPARATION METHOD |
DK0641/92 | 1992-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993023164A1 true WO1993023164A1 (en) | 1993-11-25 |
Family
ID=8095895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1993/000159 WO1993023164A1 (en) | 1992-05-14 | 1993-05-13 | Separation method |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0640014A1 (en) |
JP (1) | JPH07507959A (en) |
CN (1) | CN1081929A (en) |
AU (1) | AU4061393A (en) |
BR (1) | BR9306349A (en) |
DK (1) | DK64192D0 (en) |
MX (1) | MX9302724A (en) |
SK (1) | SK134294A3 (en) |
TW (1) | TW304886B (en) |
WO (1) | WO1993023164A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004732A1 (en) * | 1996-07-26 | 1998-02-05 | Bristol-Myers Squibb Company | SYNTHESIS OF β-LACTAM ANTIBACTERIALS USING SOLUBLE SIDE CHAIN ESTERS AND ENZYME ACYLASE |
WO2003078059A1 (en) * | 2002-03-15 | 2003-09-25 | Basf Aktiengesellschaft | Catalyst-precursor for the production of maleic acid anhydride and method for the production thereof |
WO2017186864A1 (en) * | 2016-04-27 | 2017-11-02 | Sandoz Ag | Enzymatic process for the production of beta-lactam antibiotics in the presence of particulate inoculum |
-
1992
- 1992-05-14 DK DK64192A patent/DK64192D0/en not_active Application Discontinuation
-
1993
- 1993-05-10 MX MX9302724A patent/MX9302724A/en unknown
- 1993-05-11 TW TW82103667A patent/TW304886B/zh active
- 1993-05-13 BR BR9306349A patent/BR9306349A/en not_active Application Discontinuation
- 1993-05-13 WO PCT/DK1993/000159 patent/WO1993023164A1/en not_active Application Discontinuation
- 1993-05-13 CN CN 93107082 patent/CN1081929A/en active Pending
- 1993-05-13 AU AU40613/93A patent/AU4061393A/en not_active Abandoned
- 1993-05-13 JP JP5519788A patent/JPH07507959A/en active Pending
- 1993-05-13 SK SK1342-94A patent/SK134294A3/en unknown
- 1993-05-13 EP EP93909823A patent/EP0640014A1/en not_active Withdrawn
Non-Patent Citations (5)
Title |
---|
Dialog Information Services, File 351, WPI 81-92, Dialog Accession No. 008561914, (PETR) VEB PETROCHEM SCHWEDT), "Fines Removal from Palladium-Active Carbon Catalyst - Using Sieve with Specified Mesh Width and Catalyst Vol. Flow"; & DD,A,283030, 901003, 9110. * |
Dialog Information Services, File 351: WPI 81-92, Dialog Accession No. 007453169, (KYOWA HAKKO KOGYO KK), "Prodn. of Immobilised Cells - Involves Treating Cells with Polyamine and Dialdehyde"; & JP,A,63 036 785, 880217, 8813. * |
Dialog Information Services, File 351: WPI, 81-92, Dialog Accession No. 004310425, (KONISHIROKU PHOTO KK), "Analytical Vessel for Immunoassay Use Contains Buffer liq. for Immune Reaction and Carrier for Immobilisation of Particular Components in Fluid Sample"; & JP,A,60 017 357, 850129, 8523. * |
Dialog Information Services, File 351; WPI 81-92, Dialog Accession No. 007140942, (MITK) MITSUI TOATSU CHEM INC), "Recycling Catalyst Comprises Sepq., Catalyst Components as Solid from Reaction Soln. Contq. Components and Subjecting Sepd. Components to Oxidn. Treatment"; & JP,A,62 081 350, 870414, 8720. * |
Dialog Information Services, File 5: Biosis, 68-90/May, Accession No. 6581148, Biosis Accession No. 86047699, TAKAMATSU S. et al.: "Recirculating Bioreactor-Separator System for Simultaneous Biotransformation and Recovery of Product Immobilized L Aspartate Beta-Decarboxylase Reactor System", Biotechnology Bioeng 32 (2) 1988, * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004732A1 (en) * | 1996-07-26 | 1998-02-05 | Bristol-Myers Squibb Company | SYNTHESIS OF β-LACTAM ANTIBACTERIALS USING SOLUBLE SIDE CHAIN ESTERS AND ENZYME ACYLASE |
US5922907A (en) * | 1996-07-26 | 1999-07-13 | Bristol-Myers Squibb Co. | Precursors of β-lactam antibacterials having soluble side chain esters |
US6156534A (en) * | 1996-07-26 | 2000-12-05 | Bristol-Myers Squibb Company | Synthesis of β-lactam antibacterials using soluble side chain esters and enzyme acylase |
AU727543B2 (en) * | 1996-07-26 | 2000-12-14 | Bristol-Myers Squibb Company | Synthesis of beta-lactam antibacterials using soluble side chain esters and enzyme acylase |
WO2003078059A1 (en) * | 2002-03-15 | 2003-09-25 | Basf Aktiengesellschaft | Catalyst-precursor for the production of maleic acid anhydride and method for the production thereof |
WO2017186864A1 (en) * | 2016-04-27 | 2017-11-02 | Sandoz Ag | Enzymatic process for the production of beta-lactam antibiotics in the presence of particulate inoculum |
Also Published As
Publication number | Publication date |
---|---|
SK134294A3 (en) | 1995-07-11 |
JPH07507959A (en) | 1995-09-07 |
EP0640014A1 (en) | 1995-03-01 |
BR9306349A (en) | 1998-06-30 |
CN1081929A (en) | 1994-02-16 |
DK64192D0 (en) | 1992-05-14 |
MX9302724A (en) | 1994-08-31 |
AU4061393A (en) | 1993-12-13 |
TW304886B (en) | 1997-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5470717A (en) | Method for the preparation of certain β-lactam antibiotics | |
CA2086250C (en) | Process for preparation of beta-lactams | |
EP0771357B1 (en) | PROCESS FOR PREPARATION OF $g(b)-LACTAMS AT CONSTANTLY HIGH CONCENTRATION OF REACTANTS | |
EP0865443B1 (en) | Process for the preparation of an antibiotic | |
EP0640014A1 (en) | Separation method | |
WO1992012782A1 (en) | Process for separation of two solid components | |
EP1416054B1 (en) | Simple enzymatic process for preparing cefazolin | |
EP0730036B1 (en) | Process for the enzymatic synthesis of beta-lactam antibiotics in the presence of an enzyme inhibitor | |
NL1007828C2 (en) | Complexes of beta-lactam antibiotics and 1-naphthol. | |
NL1013402C2 (en) | Method for the preparation of a beta-lactam antibiotic. | |
NL1007827C2 (en) | New complexes of beta-lactam antibiotics and poly:hydroxy-naphthalene or -quinoline compounds | |
EP0997199A1 (en) | Method for separation of solid compounds in suspension | |
US20040053912A1 (en) | Process for the preparation of a beta -lactam nucleus and the application thereof | |
EP0815256A1 (en) | Process for the preparation of a beta-lactam antibiotic | |
KR20010069097A (en) | Process for preparation of β-lactam antibiotics by enzymatic acylation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993909823 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 134294 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 1994 335793 Country of ref document: US Date of ref document: 19941110 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993909823 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993909823 Country of ref document: EP |